Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial.

Kawai T, Sako M, Arai K, Ishikawa T, Toma T, Wada T, Yada Y, Ishimura M, Doi T, Okada S, Moritake H, Izawa K, Ueki M, Inoue E, Nakamura H, Onodera M

Open source

DOI: 10.70962/jhi.20250256
Published: 2026 Sep 7
Container: Journal of human immunity
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.70962/jhi.20250256,
  title = {Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial.},
  author = {Kawai T and Sako M and Arai K and Ishikawa T and Toma T and Wada T and Yada Y and Ishimura M and Doi T and Okada S and Moritake H and Izawa K and Ueki M and Inoue E and Nakamura H and Onodera M},
  year = {2026},
  journal = {Journal of human immunity},
  doi = {10.70962/jhi.20250256},
  url = {https://doi.org/10.70962/jhi.20250256}
}

RIS

TY  - JOUR
TI  - Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial.
AU  - Kawai T
AU  - Sako M
AU  - Arai K
AU  - Ishikawa T
AU  - Toma T
AU  - Wada T
AU  - Yada Y
AU  - Ishimura M
AU  - Doi T
AU  - Okada S
AU  - Moritake H
AU  - Izawa K
AU  - Ueki M
AU  - Inoue E
AU  - Nakamura H
AU  - Onodera M
PY  - 2026
JO  - Journal of human immunity
DO  - 10.70962/jhi.20250256
UR  - https://doi.org/10.70962/jhi.20250256
ER  -

APA

T, K., M, S., K, A., T, I., T, T., T, W., Y, Y., M, I., T, D., S, O., H, M., K, I., M, U., E, I., H, N., & M, O. (2026). Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial.. Journal of human immunity. https://doi.org/10.70962/jhi.20250256

Source records

pubmed · retrieved 2026-09-25T10:26:05.102Z
europe-pmc · retrieved 2026-09-25T10:26:05.121Z
doaj · retrieved 2026-09-25T10:26:05.096Z